Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/43451
Title: | One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease | Authors: | Mankerious, Nader Toelg, Ralph Vogel, Birgit Sartori, Samantha Angiolillo, Dominick J. VRANCKX, Pascal Feng, Yihan Hernandez, Jose M. de la Torre Krucoff, Mitchell W. Bhatt, Deepak L. Spirito, Alessandro Cao, Davide Chehab, Bassem M. Kunadian, Vijay Maksoud, Aziz Picon, Hector Sardella, Gennaro Thiele, Holger Varenne, Olivier Windecker, Stephan Richardt, Gert Valgimigli, Marco Mehran, Roxana |
Issue Date: | 2024 | Publisher: | EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC | Source: | The American journal of cardiology, 225 , p. 25 -34 | Abstract: | Shortening the duration of dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) was shown to be effective and safe in patients at high bleeding risk (HBR). We aimed to investigate the effect of 1 versus 3-month DAPT on outcomes after drug-eluting stent in HBR patients with or without chronic kidney disease (CKD). Data from 3 prospective single-arm studies (XIENCE Short DAPT Program) enrolling HBR patients after successful coronary implantation of cobalt-chromium everolimus-eluting stent (XIENCE, Abbott) were analyzed. Subjects were eligible for DAPT discontinuation at 1 or 3 months if free from ischemic events. The primary end point was all-cause death or any myocardial infarction. The key secondary end point was Bleeding Academic Research Consortium Type 2 to 5 bleeding. Outcomes were assessed from 1 to 12 months after PCI. CKD was defined as baseline creatinine clearance <60 ml/min. Of 3,286 patients, 1,432 (43.6%) had CKD. One-month versus 3-month DAPT was associated with a similar 12-month risk of the primary outcome irrespective of CKD status (CKD: 9.5% vs 10.9%, adjusted hazard ratio 0.86, 95% confidence interval 0.60 to 1.22; no-CKD: 6.6% vs 5.6%, adjusted hazard ratio 1.15, 95% confidence interval 0.77 to 1.73; p interaction 0.299). Bleeding Academic Research Consortium 2 to 5 bleeding rates were numerically but not significantly lower with 1-month versus 3-month DAPT in both CKD (9.9% vs 12%) and no-CKD (6.4% vs 9.0%) patients. In conclusion, in HBR patients, 1-month versus 3-month DAPT was associated with a similar risk of ischemic complications and a trend toward fewer bleeding events at 12 months after PCI, irrespective of CKD status. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. (Am J Cardiol 2024;225:25-34) | Notes: | Mehran, R (corresponding author), Icahn Sch Med Mt Sinai, Mt Sinai Fuster Heart Hosp, New York, NY 10029 USA. roxana.mehran@mountsinai.org |
Keywords: | chronic kidney disease;DAPT;everolimus-eluting stent;high bleeding risk | Document URI: | http://hdl.handle.net/1942/43451 | ISSN: | 0002-9149 | e-ISSN: | 1879-1913 | DOI: | 10.1016/j.amjcard.2024.06.003 | ISI #: | 001267688500001 | Rights: | 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease.pdf Restricted Access | Published version | 815.99 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.